Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32-Week Randomized Phase 1b Multiple Ascending-Dose Trial
Verekitug,一种新型的TSLP受体抗体拮抗剂,用于治疗成人哮喘:一项为期32周的随机1b期多剂量递增试验
期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.70156
Singh, Dave; Brickman, Chaim M; Lloyd, Peter; Kalra, Ashish; Biswas, Subhabrata; Sinha, Arkadeep; Mulvanny, Alex; Sivapalasingam, Sumathi; Becker, Oren M; Deykin, Aaron